Key TakeawaysDupixent significantly reduces chronic obstructive pulmonary disease exacerbations by up to 34%.
The drug improves lung function rapidly and sustains these improvements...
Sanofi Showcases Pioneering Advances in Dermatology at EADV 2024
Key TakeawaysDupixent demonstrates rapid and durable efficacy in young children with moderate-to-severe atopic dermatitis.
Amlitelimab shows potential for quarterly dosing while maintaining a...
Myeloma Treatment Gets a Boost as FDA Approves Sanofi’s Sarclisa for First-Line Therapy
Key TakeawaysSarclisa has been approved for first-line treatment of multiple myeloma in transplant-ineligible patients, allowing it to compete directly with Darzalex.
The approval...
Tolebrutinib Delays Disability Progression in Secondary Progressive MS by 31%
Key TakeawaysTolebrutinib demonstrated a 31% delay in disability progression for non-relapsing secondary progressive MS (nrSPMS) patients.
The HERCULES study data, presented at ECTRIMS...
Dupixent Achieves Breakthrough in Bullous Pemphigoid Treatment
Key TakeawaysDupixent demonstrated significant improvements in disease remission and symptoms in patients with bullous pemphigoid.
Five times more patients achieved sustained disease remission...
Sanofi Partners with RadioMedix and Orano Med on Radioligand for Rare Cancers
Key TakeawaysSanofi enters a licensing agreement with RadioMedix and Orano Med for next-gen radioligand therapies targeting rare cancers.
AlphaMedix™, a lead-212-based radiopharmaceutical, shows...
Dupixent Phase 3 Study Shows Promising Results for CSU Treatment
Key TakeawaysDupixent demonstrated significant improvements in itch and hives for chronic spontaneous urticaria (CSU) patients.
The study supports Dupixent’s potential as the first...
Key Takeaways:The HERCULES Phase 3 study of tolebrutinib successfully met its primary endpoint, demonstrating a significant delay in the onset of confirmed disability...
Sanofi's subsidiary, Genzyme, has filed a significant lawsuit against Sarepta Therapeutics, claiming that Sarepta's innovative Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, infringes on...
Hemophilia A Breakthrough as NEJM Publishes Landmark Results from XTEND-Kids Phase 3 Study
The New England Journal of Medicine (NEJM) has published full results from the XTEND-Kids phase 3 study on hemophilia A treatment, highlighting the efficacy,...
